14-Hydroxydocosahexaenoic Acid.

12-lipoxygenase adds oxygen at carbon 14 of DHA, producing the hydroperoxide that is then reduced to 14-HDHA. Every molecule of 14-HDHA in the body traces back to a DHA molecule. Tissue DHA supply therefore sets the ceiling on how much of this metabolite can be formed. This is the single most important relationship for the compound.

Marine oil raises membrane DHA over weeks, which raises the substrate available to lipoxygenase. Studies measuring oxylipin panels after omega-3 supplementation consistently show DHA-derived hydroxy metabolites rising alongside the parent fatty acid. What that means for any clinical endpoint is a separate question. The substrate relationship itself is not in doubt.

12-lipoxygenase and 15-lipoxygenase act on EPA, DHA and arachidonic acid alike, so the mix of oxylipins produced tracks the mix of fatty acids present. A high EPA to DHA ratio shifts output toward EPA-derived metabolites and away from DHA-derived ones such as 14-HDHA. This is competition for enzyme access, not interference with absorption. It is why EPA-heavy and DHA-heavy oils produce different oxylipin profiles from the same total dose.

DHA has six double bonds and oxidises readily, both through enzymes and through free radical chain reactions. Tocopherol suppresses the non-enzymatic route, which keeps oxidation channelled through the controlled lipoxygenase pathway rather than producing random oxidation products. Fish oil products routinely add tocopherol for exactly this reason. It protects the oil in the bottle and the fatty acid in the membrane.

Astaxanthin sits in the membrane and quenches singlet oxygen and peroxyl radicals, which reduces uncontrolled oxidation of highly unsaturated fatty acids. Krill oil naturally contains both, which is where the pairing originates. The effect described is on oxidative stability, not on any measured change to oxylipin output in people. Read it as formulation rationale.

Krill oil carries a share of its DHA in phospholipid form rather than as triglyceride, which follows a somewhat different absorption and distribution route. Whichever vehicle delivers it, the DHA that reaches tissue is the substrate pool for this metabolite. No head-to-head study has compared vehicles on 14-HDHA output specifically. The vehicle question is about delivery, not about the downstream chemistry.

Standard marine oil raises circulating and membrane DHA, and the oxylipin panel follows. This is the ordinary route by which someone would raise this metabolite, since 14-HDHA is not itself a common supplement ingredient. Dose and duration matter more than form. Membrane incorporation takes weeks, not days.

A diet high in omega-6 fatty acids raises arachidonic acid in membranes, which competes with DHA for lipoxygenase and cyclooxygenase access. The result is a shift in the balance of oxylipins produced rather than an absolute block. Lowering omega-6 intake and raising omega-3 intake both move that balance in the same direction. The competition happens at the enzyme, not in the gut.